Allergan enters billion-dollar deal for MedImmune's Crohn's/colitis candidate; AZ regains all rights
Executive Summary
AstraZeneca's MedImmune LLC granted Allergan PLC exclusive global rights to develop and sell its MEDI2070, an interleukin-23 monoclonal antibody in Phase IIb for Crohn's disease and entering Phase II ulcerative colitis and related disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice